Related Experiment Video

Updated: Jun 27, 2025

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

2.9K

A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic

Christina Baik1,2, Michael L Cheng3, Martin Dietrich4

  • 1University of Washington, Seattle, WA, USA.

Advances in Therapy
|May 2, 2024
PubMed

Insights

The combination of encorafenib and binimetinib shows effective treatment for BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC). This targeted therapy offers durable antitumor activity and a manageable safety profile for patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • BRAF V600E mutations are a key driver in a subset of metastatic non-small cell lung cancer (NSCLC).
  • Current guidelines recommend targeted therapy combining BRAF and MEK inhibitors as first-line treatment for BRAF V600E-mutant NSCLC.

Purpose of the Study:

  • To review the efficacy and safety of encorafenib plus binimetinib in the PHAROS trial.
  • To discuss strategies for managing adverse reactions to minimize treatment discontinuation.

Main Methods:

  • Open-label, single-arm, phase 2 PHAROS trial (NCT03915951).
  • Evaluation of encorafenib (BRAF inhibitor) and binimetinib (MEK inhibitor) combination therapy.
  • Assessment of antitumor activity and safety profile.

Main Results:

  • The combination demonstrated durable antitumor activity.
  • A manageable safety profile was observed in patients with BRAF V600E-mutant metastatic NSCLC.
  • This led to FDA approval on October 11, 2023.

Conclusions:

  • Encorafenib plus binimetinib is an effective first-line treatment option for BRAF V600E-mutant metastatic NSCLC.
  • Management strategies for adverse reactions are crucial for sustained treatment.
  • The PHAROS trial results support the use of this targeted therapy combination.
Keywords:
Adverse reaction managementBRAFBinimetinibEncorafenibNon-small cell lung cancer

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
520
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K